PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Glucose

Drugs in development · updated 30 October 2026

Glucose: clinical trials and development status

NLM verified identityNot approved in the USNo EMA authorisationEstimated launch Feb 2028 – Dec 2028 (Phuturdex estimate)

As of 30 October 2026 Glucose is in 7 active clinical trials (recruiting or ongoing, phases I–III) for 13 diseases. The most advanced phase is III.

7Active trials
IIIMost advanced phase
13Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Glucose and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Chronic kidney failureIII1NCT03994471
PainII–III1NCT07493785
Substance Withdrawal SyndromeII–III1NCT07493785
Urinary retentionIII1NCT05941806
AtherosclerosisII1NCT07311330
BurnII1NCT06469970
Erectile dysfunctionII1NCT07311330
DiabetesI1NCT06558422
HyperinsulinismI1NCT06558422
Insulin resistanceI1NCT06558422
Non-alcoholic Fatty Liver DiseaseI1NCT06558422
ObesityI1NCT06558422
PrediabetesI1NCT06558422

Everything on Glucose

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch